20 citations
,
August 2014 in “Talanta” The method effectively measures drug impact on DHT levels in prostate treatments.
5 citations
,
May 2020 in “Dermatologic Therapy” 5-alpha reductase inhibitors might worsen lung recovery in COVID-19 patients, suggesting a pause in their use.
5 citations
,
January 2022 in “Clinical cancer investigation journal” Certain Dibenzo derivatives may help treat prostate cancer.
January 2004 in “Pharmaceutical biotechnology” Finasteride effectively inhibits the enzyme steroid 5 alpha-reductase II.
February 2013 in “Americanae (AECID Library)” Finasteride may reduce prostate tumor cell invasion and spread.
October 2021 in “European urology open science”
6 citations
,
January 1995 in “Neurourology and Urodynamics” Finasteride slightly improves prostate symptoms but has minimal difference from placebo.
August 2025 in “medRxiv (Cold Spring Harbor Laboratory)” 5-alpha reductase inhibitors may increase depression risk by 31%, but results vary based on comparison groups.
20 citations
,
December 2015 in “Der Urologe” Combining medications is more effective for treating benign prostatic syndrome symptoms.
24 citations
,
June 2013 in “Expert opinion on pharmacotherapy” Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.
2 citations
,
December 2004 in “PubMed” February 2026 in “The Journal of Sexual Medicine” GnRH agonists can help manage recurrent priapism in sickle cell patients, but long-term safety is unclear.
January 2014 in “프로그램북(구 초록집)” 5AR inhibitors like finasteride and dutasteride improve hair growth and slow hair loss in male pattern baldness.
47 citations
,
November 1982 in “Journal of Cardiovascular Pharmacology” Nitrendipine and nifedipine effectively block muscle contractions, while papaverine relaxes them and minoxidil needs high amounts to work.
June 2018 in “The Journal of Sexual Medicine” Finasteride does not negatively affect male reproductive function.
20 citations
,
March 2005 in “Current Medicinal Chemistry” New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
September 2014 in “PubMed Central” BPH treatments can cause sexual side effects affecting quality of life.
22 citations
,
August 2014 in “Clinical endocrinology” Taking finasteride for benign prostate hyperplasia may increase the risk of osteoporosis, especially at higher doses.
12 citations
,
August 2021 in “International Journal of Biological Macromolecules” Poria cocos polysaccharides and finasteride both help treat chronic nonbacterial prostatitis, but Poria cocos polysaccharides also improve gut health.
January 2025 in “Investigative and Clinical Urology” SHPro® improved urinary symptoms and erectile function in men and is safe.
March 2026 in “Translational Andrology and Urology” Finasteride 1 mg may help prevent prostate issues, but more research is needed to confirm its benefits.
December 2015 in “Vascular Pharmacology” Prasugrel is better than clopidogrel at preventing heart damage and improving blood flow in small heart vessels during heart artery procedures.
8 citations
,
June 2017 in “Steroids” New chemical compounds were made that effectively block an enzyme linked to prostate growth.
May 2022 in “Reactions Weekly” January 2021 in “Figshare” Finasteride's molecular properties and active sites were identified using computational methods.
3 citations
,
June 1987 in “British Journal of Dermatology” Nifedipine may help treat perniosis, improving symptoms and clearing lesions for some patients.
147 citations
,
June 2011 in “New England journal of medicine/The New England journal of medicine” 5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.
June 2021 in “European Urology” August 2013 in “Circulation Research” Finasteride reduces heart enlargement and improves heart function.
42 citations
,
August 2012 in “Psychoneuroendocrinology” Finasteride reduces certain behaviors caused by D1-like receptor agonists but not by D2-like receptor agonists in mice.